Prothena (NASDAQ:PRTA) Shares Break Above Fifty Day Moving Average – What’s Next?

Shares of Prothena Corporation plc (NASDAQ:PRTA) crossed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $8.64 and traded as high as $8.85. Prothena shares last traded at $8.77, with a volume of 741,117 shares.

Key Prothena News

Here’s some of the latest news about PRTA:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $30 price target. Separately, a Zacks article noted that the consensus target implies roughly 120% upside from recent levels, although it cautioned that price targets can be unreliable. Zacks article
• Neutral Sentiment: A short-interest report listed short interest at zero shares and a 0.0-day ratio, despite describing a large increase; the figures provide no clear directional signal. Short-interest information
• Negative Sentiment: HC Wainwright lowered several future EPS forecasts, including FY2027–FY2029 and FY2030, while maintaining its Buy rating. It also cut its Q4 2026 estimate to a $0.44-per-share loss from a $0.38 loss. Prothena’s latest reported quarter also missed expectations: EPS was a $0.32 loss versus a $0.23 loss forecast, and revenue was $0.62 million versus $9.58 million expected. Analyst estimates and results

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Weiss Ratings lowered Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 29th. Wall Street Zen downgraded shares of Prothena from a “buy” rating to a “hold” rating in a research note on Saturday, July 25th. UBS Group restated a “buy” rating on shares of Prothena in a report on Friday, July 24th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Prothena in a report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Prothena Stock Performance

The firm has a market cap of $448.29 million, a P/E ratio of -18.19, a P/E/G ratio of 1.83 and a beta of -0.20. The firm’s fifty day simple moving average is $8.60 and its 200 day simple moving average is $9.18.

Prothena (NASDAQ:PRTA) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.09). Prothena had a negative net margin of 45.44% and a negative return on equity of 9.98%. The company had revenue of $0.62 million for the quarter, compared to analysts’ expectations of $9.58 million. On average, equities research analysts predict that Prothena Corporation plc will post 0.13 earnings per share for the current year.

Insider Buying and Selling at Prothena

In related news, major shareholder William P. Scully bought 140,000 shares of the business’s stock in a transaction on Monday, November 9th. The shares were bought at an average price of $8.53 per share, for a total transaction of $1,194,200.00. Following the completion of the purchase, the insider directly owned 977,000 shares of the company’s stock, valued at approximately $8,333,810. This trade represents a 16.73% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders acquired 1,157,500 shares of company stock worth $9,849,050. Corporate insiders own 10.40% of the company’s stock.

Institutional Trading of Prothena

A number of institutional investors have recently modified their holdings of PRTA. Versant Capital Management Inc raised its stake in shares of Prothena by 179.1% during the 3rd quarter. Versant Capital Management Inc now owns 5,704 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 3,660 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Prothena in the second quarter valued at approximately $148,000. Sei Investments Co. acquired a new stake in Prothena in the first quarter valued at approximately $168,000. Chicago Partners Investment Group LLC grew its holdings in Prothena by 59.8% in the third quarter. Chicago Partners Investment Group LLC now owns 25,779 shares of the biotechnology company’s stock worth $211,000 after purchasing an additional 9,650 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new position in Prothena in the third quarter worth $239,000. 97.08% of the stock is currently owned by institutional investors.

About Prothena

Prothena Corporation plc is a clinical-stage biotechnology company developing treatments for diseases associated with protein misfolding and dysfunction. Its research focuses on using antibodies and other biologic approaches to target proteins implicated in neurological and systemic disorders. The company’s pipeline has included programs for Parkinson’s disease, Alzheimer’s disease and AL amyloidosis. Its investigational therapies include prasinezumab, developed in collaboration with Roche, and programs targeting amyloid beta and transthyretin-related disease.